Temozolomide radiochemotherapy for high-grade glioma patients with hemodialysis: a case series of 7 patients.

Journal: Neuro-oncology practice
Published Date: Dec 3, 2019

Abstract

BACKGROUND: The pharmacokinetics of temozolomide (TMZ) in patients with severe renal impairments (creatinine clearance, <36 mL/min/m) or in hemodialysis (HD) patients has not been investigated. TMZ and its metabolic products are mainly excreted in urine, as retention of these in the body may result in increased adverse events in HD patients.

Authors

  • Jun Muto
    Department of Neurosurgery, Fujita Health University, Japan.
  • Tomoo Matsutani
    Department of Neurosurgery, Chiba University, Japan.
  • Ryosuke Matsuda
    Department of Neurosurgery, Nara Medical University, Japan.
  • Masashi Kinoshita
    Department of Neurosurgery, Kanazawa University, Japan.
  • Mitsuteru Oikawa
    Department of Neurosurgery, Nakamura Memorial Hospital, Japan.
  • Johan Pallud
    Department of Neurosurgery, Sainte-Anne Hospital, Paris, France.
  • Hikaru Sasaki
    Department of Neurosurgery, Keio University School of Medicine, Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals